<DOC>
	<DOCNO>NCT00141960</DOCNO>
	<brief_summary>Gastroesophageal reflux disease ( GERD ) consider associate mucosal damage esophagus heartburn , may sometimes interfere daily activity due likely reflux acid gastric content . While patient give diagnosis GERD exhibit endoscopically obvious impairment esophageal mucous membrane , subjective symptom non-erosive GERD include heartburn . But drug launch Japan , target non-erosive GERD . This study examine efficacy safety famotidine subject non-erosive GERD .</brief_summary>
	<brief_title>Famotidine Subjects With Non-erosive Gastroesophageal Reflux Disease</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<criteria>Patients heartburn nonerosive gastroesophageal reflux disease . Patients diseases interfere evaluation efficacy safety study . Patients receive and/or receive prior enrollment treatment interfere evaluation efficacy safety study . Patients severe cardiovascular , hepatic , renal hematological disorder . Patients allergic history drug allergy H2RA . Patients history malignant tumor . Patients pregnant lactate mother . Patients participate clinical study less 12 week prior submit inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Treatment efficacy</keyword>
	<keyword>Treatment effectiveness</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Reflux , Gastroesophageal</keyword>
	<keyword>GERD</keyword>
</DOC>